Found: 64
Select item for more details and to access through your institution.
Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B.
- Published in:
- Mycoses, 2011, v. 54, n. 4, p. 365, doi. 10.1111/j.1439-0507.2010.01880.x
- By:
- Publication type:
- Article
Relevance of bone marrow histology in challenging cases of Acute Myeloid Leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1212752
- By:
- Publication type:
- Article
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.
- Published in:
- Current Oncology, 2022, v. 29, n. 3, p. 1455, doi. 10.3390/curroncol29030122
- By:
- Publication type:
- Article
Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 1, p. 147, doi. 10.1111/bjh.18749
- By:
- Publication type:
- Article
Thrombopoietin receptor agonists increase splenic regulatory T‐cell numbers in immune thrombocytopenia.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 5, p. 916, doi. 10.1111/bjh.18309
- By:
- Publication type:
- Article
Of drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 6, p. 943, doi. 10.1111/bjh.18206
- By:
- Publication type:
- Article
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 559, doi. 10.1111/bjh.17890
- By:
- Publication type:
- Article
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 2, p. 356, doi. 10.1111/bjh.17192
- By:
- Publication type:
- Article
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 35, doi. 10.1111/bjh.15497
- By:
- Publication type:
- Article
Non-hepatosplenic extramedullary haematopoiesis in primary myelofibrosis.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 3, p. 271, doi. 10.1111/bjh.12701
- By:
- Publication type:
- Article
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 427, doi. 10.1007/s00277-023-05556-0
- By:
- Publication type:
- Article
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2005, doi. 10.1007/s00277-020-04392-w
- By:
- Publication type:
- Article
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 8, p. 1885, doi. 10.1007/s00277-019-03705-y
- By:
- Publication type:
- Article
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
- Published in:
- 2018
- By:
- Publication type:
- journal article
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
- Published in:
- 2014
- By:
- Publication type:
- Letter
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5027, doi. 10.3390/cancers15205027
- By:
- Publication type:
- Article
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
- Published in:
- Cancers, 2023, v. 15, n. 14, p. 3706, doi. 10.3390/cancers15143706
- By:
- Publication type:
- Article
Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1311, doi. 10.3390/cancers13061311
- By:
- Publication type:
- Article
Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 2, p. 281, doi. 10.1111/ejh.13547
- By:
- Publication type:
- Article
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC".
- Published in:
- Cancer Medicine, 2023, v. 12, n. 3, p. 3180, doi. 10.1002/cam4.5158
- By:
- Publication type:
- Article
The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 18, p. 6310, doi. 10.1002/cam4.4179
- By:
- Publication type:
- Article
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 5, p. 1726, doi. 10.1002/cam4.3778
- By:
- Publication type:
- Article
"Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key?
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 3, p. 272, doi. 10.1111/ejh.13282
- By:
- Publication type:
- Article
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 5, p. 323, doi. 10.1016/j.clml.2024.01.008
- By:
- Publication type:
- Article
CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S329, doi. 10.1016/S2152-2650(21)01772-9
- By:
- Publication type:
- Article
Poster: CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S225, doi. 10.1016/S2152-2650(21)01419-1
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00834-6
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00392-1
- By:
- Publication type:
- Article
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 6, p. 1, doi. 10.1038/s41408-020-0333-2
- By:
- Publication type:
- Article
Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 401, doi. 10.1002/hon.2851
- By:
- Publication type:
- Article
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 409, doi. 10.1002/hon.2843
- By:
- Publication type:
- Article
Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 4, p. 607, doi. 10.1002/hon.2765
- By:
- Publication type:
- Article
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 7, p. E159, doi. 10.1002/ajh.25102
- By:
- Publication type:
- Article
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 7, p. E135, doi. 10.1002/ajh.24022
- By:
- Publication type:
- Article
Coexistence of primary AL amyloidosis and POEMS syndrome: Efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 2, p. 131, doi. 10.1002/ajh.21581
- By:
- Publication type:
- Article
Jordans' anomaly in a new neutral lipid storage disease.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 4, p. 254, doi. 10.1002/ajh.21186
- By:
- Publication type:
- Article